Byler Disease Market Analysis - Global Industry Size, Share, Trends and Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC2353

Gradual increase in number of patients suffering from rare disease and increasing government spending on development of advanced healthcare in order to provide advanced care are major factors expected to drive the growth of global Byler disease market.

Byler is rare diseases witnessed among the new born babies that cannot release bile, a fluid that helps the body digest food. The total number of Americans living with a rare disease is estimated at between 25-30 million. According to article published by Journal of Rare Disorders, there are approximately 7,000 classified rare disorders and around 70% of these disorders do not have treatment. Government of developed and developing counties is spending high in the R&D activities and development of new drugs. The investment in medical and health research and development (R&D) in the US grew by 27% over the five-year period from 2013 to 2017.  The National Institutes of Health (NIH) accounted for major share of federal spending in medical and health research in 2017 which is US$32.4 billion.

In collaboration with the public players government is focused on strengthening the home care delivery system. They are focused on providing advanced care for patients suffering from liver disorder. According to Centers for Disease Control and Prevention, liver disease is estimated to witness growth rates increases 9.9% every year. High government spending for the development of present hospital infrastructure in order to provide enhanced care to patient by adopting advanced medical devices is expected to impact the growth of Byler disease market. Deployment of various new surgical equipments such as laser and cryo devices is expected to hospitals to aid in providing the required treatment to rare diseases patients.  Spending on development of smart healthcare by the government of developed countries is increasing they are focused to deliver enhance care. Integration of AI in devices that aid in high precision during the surgery is gaining traction. Medical device manufactures are focused on providing advanced products

Factors such as high cost associated to treatment & medical devices, high cost for new drug development and lack of awareness among patients related to rare diseases are expected to hamper the growth of global Byler disease market. The cost associated to treatment of the rare diseases is high due to unavailability of required technology and lack of skilled professionals. The development of a new drug costs around 2.6 billion U.S. dollars and can take up to 15 years. In addition, stringent government regulations related to product approval and lack of advanced infrastructure for adoption of advanced devices are factors expected to challenge the growth of global Byler disease market. However, increasing investment by the major players for R&D activities, increasing awareness activities by the government related to rare disease and high spending on development medical infrastructure by developing government are factors expected to create new opportunities for players operating in the target market. In addition, increasing public-private partnership for development of innovative treatment is expected to support the growth of revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global Byler disease market due to increasing patients suffering from rare diseases. In addition, increasing investment for R&D activities by the universities and academic institute is expected to support the growth of target market. Academic and research institutions, including colleges and universities, independent research institutes (IRIs), and independent hospital medical research centers increased their spending, dedicating more than US$14.2 billion of their own funds to medical and health R&D in 2017.

Presence of large number of players operating in the country, focus on introduction of innovative treatment solution, and increasing product pipeline under clinical trials are factors expected to augment the growth of regional market.

Competitive Landscape      

The global smart wallet market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market

 Global Byler Disease Market

Analysis Period

 2016 – 2027

Base Year

 2019

Forecast Data

 2020 – 2027

Market Stratification

 Treatment, End Use, and Geography

Regional Scope

 North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Coverage

 Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Byler Disease Market Segment Analysis, 2019

The global Byler disease market is segmented into treatment and end use. The treatment segment is bifurcated into medical treatment and surgical treatment. Among treatment the surgical treatment is expected to witness significant growth in the near future due to increasing demand for minimal invasive surgical procedures from patients and adoption of AI in surgical devices for high accuracy and better results. The end use segment is divided into research centers, hospitals, clinics, and others. Among the end use the hospitals segment is expected to account for major revenue share in the target segment due to up-gradation plan by the government in order to support the adoption of advanced medical devices and provide enhanced care to patients.

The players profiled in the report Merck & Co. Inc., Sanofi AG, Novartis AG, Bayer AG, GlaxoSmithKline plc, AstraZeneca PLC, Pfizer Inc, Bristol-Myers Squibb Company, Gilead Science Inc., and Johnson & Johnson Private Limited.

Market Segmentation

Market By Treatment

Medical Treatment

  • Phenobarbital or Rifampin
  • Others

Surgical Treatment

  • Laser surgery
  • Cryosurgery
  • Laparoscopic surgery
  • Others

Market By End Use

Research Centers

Hospitals

Clinics

Others

Market By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa


Cart Summary


1